drugset / Trial / NCT07533266
Study to Evaluate the Efficacy and Safety of Fexuprazan in Prevention of NSAIDs Induced Peptic Ulcer
RandomizedParallel-groupQuadruple-blindPrevention
Summary
The study aims to demonstrate the preventive effect of Fexuprazan 20 mg for peptic ulcer is non-inferior to that of Lansoprazole 15 mg in terms of prevention of peptic ulcer and confirm the safety of Fexuprazan 20 mg.
Timeline
- Start
- 2026-04
- Primary completion
- 2027-12
- Completion
- 2027-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ABEPRAZAN | Small molecule | 20 mg | Oral |
| Comparator | Lansoprazole | Other / unclassified | 15 mg | Oral |
Indications
No indication recorded.